MMI

What MMI does

MMI (Medical Microinstruments, Inc.) is a privately held medical device company founded in 2015 near Pisa, Italy, and now headquartered in Jacksonville, Florida following a 2022 corporate domicile relocation. The company develops the Symani Surgical System, a robotic platform specifically designed for open microsurgery and microvascular procedures that enables surgeons to operate on anatomical structures as small as 0.1 millimeters in diameter—a precision level not achievable with manual microsurgery or general-purpose surgical robots such as Intuitive Surgical's da Vinci. MMI complements the Symani platform with proprietary NanoWrist instruments (Scissors and Forceps, FDA 510(k) cleared in December 2025), the Synaptix Digital Surgery Platform for visual and workflow enhancements, and the world's first Robotic Suture purpose-built for robotic microsurgery, developed in partnership with Kono Seisakusho (Crownjun).\n\nMMI generates revenue through capital equipment sales of the Symani Surgical System to hospitals and academic medical centers, supplemented by recurring consumables revenue from proprietary instruments and sutures. The company pursues a direct enterprise sales motion in the U.S. and Western Europe and uses exclusive distribution partnerships in Asia-Pacific and Eastern Europe—Gunze Medical Limited for Japan and Synektik Group covering six Eastern European countries. Following FDA authorization for Symani in April 2024, MMI holds regulatory approvals across 35 countries. The establishment of CPT code 1019T and a CMS payment rate for lymphovenous bypass surgery effective January 1, 2026 creates a dedicated reimbursement pathway supporting U.S. hospital adoption.\n\nMMI's commercial strategy is anchored in clinical evidence generation, including FDA-approved IDE studies such as the REMIND trial exploring robotic microsurgical intervention for Alzheimer's disease. The company targets high-acuity microsurgical applications including lymphatic repair, reconstructive surgery, and emerging neurodegenerative disease interventions. With 101–250 employees and approximately $200 million in cumulative funding across a 2022 Series B ($75 million, led by Deerfield) and a 2024 Series C ($110 million, led by Fidelity Management & Research Company), MMI is investing in global commercialization, technology development, and clinical evidence generation.

Name

MMI

Legal name

Medical Microinstruments, Inc.

Website

https://mmimicro.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

MMI develops the Symani Surgical System, a robotic platform enabling open microsurgery on vessels as small as 0.1mm. The company sells its FDA-authorized system, NanoWrist instruments, and proprietary Robotic Suture to academic medical centers and specialty hospitals in 35 countries.

Ownership category

akta.pro rank

Product category

Surgical Robotics — Microsurgery

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity) (HLAHADAE), Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG), Perioperative Supply Chain, Instruments & Surgical Logistics (HLAFAIAO)

Keywords

• Robotic microsurgery
• Surgical robotics
• Microvascular surgery
• Reconstructive microsurgery
• Robotic surgical instruments

Headquarters

HQ city

Jacksonville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Symani Surgical System Hardware Sales: MMI generates revenue from the sale of its Symani Surgical System robotic platform to hospitals and medical centers. The system is commercially available in the US following FDA authorization and CE-marked in Europe.
2. Surgical Instruments and Accessories: Revenue from proprietary consumables including NanoWrist instruments and Robotic Suture designed specifically for use with the Symani system.
3. Reimbursement for Lymphatic Procedures: Following establishment of CPT code 1019T for lymphovenous bypass surgery and CMS payment rates effective January 2026, hospitals can now submit direct claims for lymphedema treatment procedures using MMI's system, creating reimbursement pathway.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

MMI develops and sells the Symani Surgical System, a robotic platform specifically designed for microsurgical procedures, enabling surgeons to operate on vessels as small as 0.1 millimeters in diameter. The system is complemented by proprietary NanoWrist Instruments (Scissors and Forceps) for soft tissue dissection, a purpose-built Robotic Suture developed with Kono Seisakusho (Crownjun), and the Synaptix Digital Surgery Platform for visual enhancements and operating room workflow. The company sells the platform and consumables to hospitals and academic medical centers globally.

Product overview

MMI offers a unified surgical robotics platform centered on the Symani Surgical System, the only commercially available robotic platform in the U.S. designed specifically for reconstructive microsurgery. The platform comprises NanoWrist Instruments (scissors, forceps, and other wristed microsurgical tools) for soft tissue dissection and anastomosis, the Synaptix Digital Surgery Platform providing visual enhancements and workflow efficiencies, and the proprietary Robotic Suture purpose-built for robotic microsurgical procedures. The system enables surgeons to operate on vessels as small as 0.1 millimeters in diameter.

Differentiator

Problem solved

Functional benefit

Brands

• Symani Surgical System: Robotic microsurgery platform with NanoWrist instruments designed for microvascular and microsurgical procedures
• NanoWrist Instruments
• Robotic Suture
• Synaptix Digital Surgery Platform

Products and services

• Symani Surgical System The main robotic surgical platform from MMI, specifically designed for microvascular and microsurgical procedures. FDA-authorized and CE-marked, enabling surgeons to operate on vessels as small as 0.1 millimeters in diameter. Sold to hospitals and academic medical centers for reconstructive microsurgery.
• NanoWrist Scissors and Forceps The world's first fully wristed robotic instruments specifically designed for dissection in open microsurgery. FDA 510(k) cleared for soft tissue dissection, expanding the Symani system's capabilities beyond anastomosis. Consumables used with the Symani Surgical System.
• Robotic Suture The world's first suture purpose-built for robotic microsurgery, developed in partnership with Kono Seisakusho Co., Ltd. (Crownjun). Features shorter length (approximately one-third to one-half of conventional micro sutures), two needle curvature options, and direct surgeon loading capabilities. Targets the $446 million global micro-sutures market.
• Synaptix Digital Surgery Platform The first digital platform built for open microsurgery, enabling visual enhancements and workflow efficiencies in the operating room when used with the Symani Surgical System.

Quantifiable outcome

• Enables surgery on vessels as small as 0.1 millimeters in diameter
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Gunze Medical LimitedcoreChannel Partner/ Reseller/ Distributor · 5 June 2026Exclusive distribution agreement for Japan, one of the key Asia-Pacific markets. Asia-Pacific represents the fastest growing microsurgery market globally, and this partnership accelerates MMI's regional expansion following regulatory approvals.
• Synektik GroupcoreChannel Partner/ Reseller/ Distributor · 5 June 2026Partnership covering six Eastern European countries, expanding MMI's European market presence beyond existing operations in Italy and other direct markets.
• Kono Seisakusho Co., Ltd. (Crownjun)coreStrategic or Co-development Partner · 9 April 2026Joint development partnership to create the world's first Robotic Suture purpose-built for the Symani Surgical System. The suture features optimized dimensions and needle configurations for robotic microsurgery, targeting the $446 million global micro-sutures market.
• Leading U.S. and European Research InstitutionscoreStrategic or Co-development Partner · 20 November 2025MMI is partnering with leading research institutions in the U.S. and Europe for the REMIND clinical study, a first-of-its-kind feasibility study using the Symani Surgical System to perform microsurgical intervention in Alzheimer's patients.
• USF Health and Tampa General HospitalcoreStrategic or Co-development Partner · 1 January 2024Academic medical center partnership established during a 2024 trade mission to Italy. USF Health and Tampa General Hospital acquired the Symani Surgical System and began offering robotic microsurgery for lymphedema patients, with Dr. Nicholas Panetta performing lymphatic-venous bypass procedures.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Stryker: Maker of the Mako robotic-arm assisted surgery system, primarily for orthopedic procedures. While not a direct microsurgery competitor, Stryker is a relevant surgical robotics incumbent with the resources to enter adjacent specialties.
• Zimmer Biomet: Developer of the ROSA robotic system for neurosurgery, spine, and orthopedics. Comparable as a surgical robotics incumbent operating in adjacent high-precision surgical niches that overlap with MMI's microsurgical focus.
• Smith+Nephew: Maker of the CORI handheld robotic-assisted surgery system for orthopedics. Relevant as a diversified medtech incumbent with robotics capabilities and global commercial reach overlapping with MMI's hospital customer base.
• Globus Medical: Spine and orthopedic robotics company (ExcelsiusGPS) and one of the top three autonomous robotic surgery patent assignees alongside MMI. Comparable as a high-precision surgical robotics incumbent with overlapping IP positioning.
• Medtronic: Developer of the Hugo robotic-assisted surgery platform. As a diversified medical device leader, Medtronic competes broadly with MMI in surgical robotics and possesses the scale and capital to expand into microsurgical indications.
• Johnson & Johnson (Ethicon / Auris Health): Owner of the MONARCH platform and developer of the Ottava robotic surgery system. J&J's medtech scale and R&D capacity position it as a strategic competitor that could extend into microsurgical robotics over time.
• Intuitive Surgical: Maker of the da Vinci surgical robotic system, the dominant incumbent in robotic surgery. While da Vinci focuses on larger-scale laparoscopic procedures rather than sub-millimeter microsurgery, it is the principal competitive reference point and potential disruptor for MMI's robotic surgery platform.

Direct peers

• Corindus (Siemens Healthineers): Developer of the CorPath GRX robotic system for vascular interventions. Closely comparable as a niche surgical robotics platform targeting precision catheter-based procedures rather than broad laparoscopic surgery.

Emerging players

• Penumbra: Developer of the REAL Robotic System for peripheral vascular interventions. Comparable as an emerging robotics player focused on vascular and specialty surgical applications adjacent to MMI's microsurgical niche.
• Moon Surgical: A French-based emerging surgical robotics company developing the Maestro system for laparoscopic soft tissue surgery. Comparable as a venture-backed European surgical robotics peer pursuing a category-positioning strategy similar to MMI's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mmimicro
• Facebookfacebook.com/mmimicro
• LinkedInlinkedin.com/company/mmimicro

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MMI